EDRIA
BMRN icon

Edmonds Duncan Registered Investment Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Edmonds Duncan Registered Investment Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,633
Closed -$256K – 139
2023
Q1 		$256K Sell
2,633
-113
-4% -$11.7K 0.08% 110
2022
Q4 		$284K Hold
2,746
– – 0.09% 97
2022
Q3 		$233K Buy
+2,746
New +$245K 0.08% 105

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Edmonds Duncan Registered Investment Advisors's BMRN Position: Q2 2023 in Review

Edmonds Duncan Registered Investment Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2023, closing a stake of 2,633 shares — an estimated $256K sold.

Edmonds Duncan Registered Investment Advisors first reported a position in BMRN in Q3 2022 and held it in 3 quarters. The position peaked at $284K in Q4 2022. 558 funds tracked by Wall St. Rank hold BMRN as of Q2 2023.

  • Edmonds Duncan Registered Investment Advisors reported no remaining BioMarin Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Edmonds Duncan Registered Investment Advisors sold 2,633 BioMarin Pharmaceuticals shares in Q2 2023, an estimated $256K.
  • Edmonds Duncan Registered Investment Advisors first reported a position in BioMarin Pharmaceuticals in Q3 2022 and held it in 3 quarters.
  • Edmonds Duncan Registered Investment Advisors's BioMarin Pharmaceuticals position peaked at $284K in Q4 2022.
  • 558 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2023.

Based on Edmonds Duncan Registered Investment Advisors's 13F filing for Q2 2023, filed 6 Jul 2023.